We aimed to stratify clinical risk among patients with high‐volume metastatic hormone‐sensitive prostate cancer (mHSPC) treated with first‐line androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT).
Keiichiro Miyajima, T. Yanagisawa, Wataru Fukuokaya et al.· International journal of uro...· 0 citations
Differences in tumor biology, ethnicities, and healthcare structures across populations may contribute to variability in oncologic outcomes. This study compared baseline characteristics and oncologic outcomes of Japanese and German metastatic hormone‐sensitive prostate cancer (mHSPC) patients.
Mike Wenzel, Keiichiro Miyajima, M. Filzmayer et al.· International journal of uro...· 1 citation
To evaluate perioperative safety, pathological outcomes, and oncological outcomes of en bloc resection of bladder tumor (ERBT) in a large multicenter real‐world cohort.
T. Yanagisawa, A. Matsukawa, K. Iwatani et al.· International journal of uro...· 0 citations
Available evidence does not support a strong or consistent association between dietary factors and bladder cancer (BC) risk, and patients should be informed that dietary modifications alone are unlikely to meaningfully alter their BC risk.
Keiichiro Miyajima, Marcin Miszczyk, Navid Roessler et al.· BJU International· 0 citations
Preliminary, hypothesis-generating findings suggest ML may predict EV-related toxicities, but single train-test split, small event counts, and lack of external validation preclude clinical use.
K. Sridharan, Mattia Alberto Di Civita, G. Sivaramakrishnan et al.· Expert Review of Anticancer...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
